Phase 4
Completed N=41
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis
Source: ClinicalTrials.gov NCT00690833 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Investigator Global Assessment at Week 4 — 2.3 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Investigator Global Assessment at Week 4 |
2.3 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, age 3 months or greater.
- Subjects must have diagnosis of mild to moderate atopic dermatitis by an investigator (a 2 or 3 on the IGA scale).
- Subjects must have >2% BSA involvement to be enrolled.
- Informed consent of participation must be given by parent or guardian if he or she is 130 gm of cream in a 4 week period.
- Pregnant women and women who are breastfeeding are to be excluded. Women of childbearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control. Use of desonide in pregnant subjects is controversial and is only to be used when benefits outweigh the risks.
Data sourced from ClinicalTrials.gov (NCT00690833). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.